Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 66 от 240

Набира участници

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Advanced Hepatocellular Carcinoma (HCC)

To evaluate the efficacy and immune microenvironment changes in advanced hepatocellular carcinoma (HCC) patients receiving different first-line immunotherapy.

Начало: 01.09.2025 Край: 01.09.2028 Възраст: от 18 г.

China Fudan University NCT07147101

Набира участници

Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis

Allergic Bronchopulmonary Aspergillosis Severe Asthma ABPA

An open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis

Начало: 01.09.2025 Край: 01.12.2026 Възраст: 18–75 г.

China Qianfoshan Hospital NCT07530770

Набира участници

Gummy Smile and Altered Passive Eruption Prevalence

Altered Passive Eruption of Teeth

This observational epidemiological study aims to assess the prevalence of gummy smile and altered passive eruption in a young adult population, with a focus on the second sextant. Periodontal and aesthetic parameters, along with patient-reported discomfort, will be analyzed to identify potential correlations and underlying anatomical factors.

Начало: 01.09.2025 Край: 01.12.2026 Възраст: 18–50 г.

Italy University of Roma La Sapienza NCT07548398

Набира участници

Mechanical Bowel Preparation in Laparoscopic Right Hemicolectomy With Intracorporeal Anastomosis

Colon Cancer

This study is a randomized controlled trial conducted at University Medical Center Ho Chi Minh City to evaluate the role of mechanical bowel preparation (MBP) in patients undergoing laparoscopic right hemicolectomy with totally intracorporeal anastomosis for colon cancer. Mechanical bowel preparation is commonly used before colorectal surgery to reduce bowel contents and potentially decrease the risk of postoperative infections. However, its benefit remains controversial, particularly in intracorporeal anastomosis, where intra-abdominal contamination may influence surgical outcomes. In this study, eligible patients will be randomly assigned to one of two groups: with or without mechanical bowel preparation before surgery. The study aims to compare intraoperative events, postoperative complications, and recovery outcomes between the two groups. The primary outcome is the rate of surgical site infection (SSI) within 30 days after surgery. Secondary outcomes include intraoperative fecal contamination, anastomotic leakage, postoperative ileus, operative time, and recovery parameters such as time to first bowel movement and length of hospital stay. The findings of this study are expected to clarify the role of mechanical bowel preparation in reducing postoperative infections and improving surgical outcomes in patients undergoing laparoscopic right hemicolectomy.

Начало: 01.09.2025 Край: 31.10.2027 Възраст: от 18 г.

Vietnam University Medical Center Ho Chi Minh City (UMC) NCT07546565

Набира участници

Neural Mechanisms of Interpersonal Expectations on Negative Affect

Negative Affectivity Non-invasive Brain Stimulation Placebo Effect Expectations

The goal of this clinical trial is to learn whether non-invasive brain stimulation, called transcranial temporal interference stimulation (tTIS), can reduce negative affect, and how expectations shaped by care providers influence these effects. The main questions this study aims to answer are: (1)Does active tTIS reduce negative affect more effectively than sham (inactive) tTIS? (2)Do positive treatment expectations enhance the effects compared to negative expectations? Participants will: (1) Receive either active or sham tTIS. (2) Be provided with positive or negative messaging regarding treatment effectiveness. (3) Interact with care providers and complete assessments measuring negative affect and physiological responses.

Начало: 01.09.2025 Край: 03.03.2028 Възраст: 18–55 г.

United States Trustees of Dartmouth College NCT06980090

Набира участници

Early Partial Weight-bearing May Improve Functional Recovery Without Increasing Complications Despite This Potential, Limited Randomized Studies Have Evaluated Early Weight-bearing After Pelvic Fixation Surgeries

Pelvic Fractures Weight Bearing

The goal of this randomized clinical trial is to compare between the effect of immediate weight bearing (WB) versus delayed weight bearing in improving function, pain, gait, quality of reduction radiologically, muscle strength, and quality of life outcomes in individuals who underwent specific pelvic fixation surgeries.

Начало: 31.08.2025 Край: 01.06.2026 Възраст: 18–55 г.

Egypt Assiut University NCT07538726

Набира участници Фаза 2/3

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Gastroenteropancreatic Neuroendocrine Tumors

There is limited evidence regarding the benefit of adding somatostatin analogs to molecular targeted agents for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with poor prognostic factors. This trial is conducted to evaluate sirolimus for injection (albumin bound) combined with octreotide long-acting injection in patients with unresectable or recurrent GEP-NETs.

Начало: 29.08.2025 Край: 29.08.2028 Възраст: от 18 г.

China CSPC ZhongQi Pharmaceutical Technology Co., Ltd. NCT07165886

Набира участници

Prospective Pathology Foundation Models

Pancancer

Histopathology remains the gold standard for disease diagnosis, yet faces challenges including pathologist shortages and diagnostic model limitations. This underscores the critical need to develop deep learning-based pathology foundation models integrating prospective imaging and clinical data. Such models would enhance diagnostic accuracy and efficiency, enabling tumor grading, histo-molecular classification, and intelligent chemotherapy guidance - ultimately optimizing clinical workflows. However, a critical gap remains: the absence of prospectively validated, pan-disease pathology foundation models. Developing clinically validated models is therefore imperative.

Начало: 28.08.2025 Край: 01.08.2028 Възраст: 18–75 г.

China Nanfang Hospital, Southern Medical University NCT07157618

Набира участници Фаза 1

A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

Overweight or Obesity Healthy

The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Начало: 28.08.2025 Край: 01.11.2026 Възраст: 18–65 г.

Singapore, United States Eli Lilly and Company NCT07152002

Набира участници Фаза 2

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

IgAN C3G Complement-mediated Kidney Disease IgA Nephropathy (IgAN) +1

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.

Начало: 28.08.2025 Край: 01.06.2029 Възраст: от 18 г. Лечение

Australia, Hong Kong, South Korea +3 ADARx Pharmaceuticals, Inc. NCT06989359

Набира участници

Cold Water and Decision-Making

Behavior Stress Quality of Life Psychological Wellbeing

The behavioral within-subject cross-over design study "CoVa" aims to investigate the effect of a short-term full-body cold-water immersion vs. warm-water immersion control on value-based choice, psychological well-being, and peripheral physiology.

Начало: 28.08.2025 Край: 31.12.2026 Възраст: 18–40 г.

Germany German Institute of Human Nutrition NCT06908447

Набира участници Фаза 3

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

Hereditary Angioedema HAE Hereditary Angioedema - Type 1 Hereditary Angioedema - Type 2

This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.

Начало: 28.08.2025 Край: 31.12.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Austria +16 ADARx Pharmaceuticals, Inc. NCT06960213

Набира участници

Optimizing Timing of Cesarean Delivery Consent on Labor and Delivery

Pregnancy Informed Consent

Nationally, 32.1% of pregnant patients deliver via cesarean delivery, including both patients who undergo a planned cesarean delivery and patients who intend to undergo vaginal delivery and are recommended to deliver via cesarean delivery. The investigators aim to understand how to optimize the patient experience for patients who present to the hospital intending to deliver vaginally but are recommended to deliver via cesarean delivery (an unplanned cesarean delivery). Practices regarding timing of informed consent for possible cesarean delivery vary widely across hospitals in the United States; some institutions will consent every patient on admission to the hospital for possible cesarean delivery, whereas some institutions consent patients for possible cesarean delivery only if a patient's clinical course suggests cesarean delivery may be indicated. This study aims to determine optimal timing for consent for possible cesarean delivery by randomizing patients to either be consented for possible cesarean delivery on admission to the hospital or if it appears to be clinically indicated. This study will only assess altered timing of a surgical consent process and will not impact the clinical care participants receive. After delivery, participants will share their experiences with the consent process and with their overall childbirth experience.

Начало: 27.08.2025 Край: 01.05.2027 Възраст: от 18 г.

United States Duke University NCT07117708

Набира участници

SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment

Parkinson Disease

The purpose of the study is to generate real-world evidence data for the on-demand treatment with SL-APO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment to ultimately understand their influence in patient satisfaction, treatment persistence, and the balance between effectiveness and safety. The data may help optimize titration approaches to better meet the patient's needs.

Начало: 27.08.2025 Край: 01.02.2028 Възраст: от 18 г.

Germany Bial - Portela C S.A. NCT07145190

Набира участници Фаза 1

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Renal Cell Carcinoma Urothelial Carcinoma Castration-resistant Prostate Cancer

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

Начало: 27.08.2025 Край: 01.02.2029 Възраст: от 18 г.

United States Deciphera Pharmaceuticals, LLC NCT06966024

Набира участници Фаза 1

3D1015 Injection for Patients With mCRPC

Metastatic Castration-resistant Prostate Cancer, mCRPC

This open-label clinical study investigates 3D1015 Injection (Lu 177-PSMA-3D1015) in adult males with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Participants will receive intravenous infusions of 3D1015, with treatment regimens dynamically individualized to optimize patient safety and outcomes. The primary objectives are to assess the safety, tolerability, and dosimetry of the injection. Secondary objectives include evaluating preliminary anti-tumor efficacy and exploring the optimal dosing regimen.

Начало: 27.08.2025 Край: 31.12.2027 Възраст: от 18 г.

China Chunjing Yu NCT07537010

Набира участници Фаза 3

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Metastatic Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma

This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot be surgically removed or has spread from the stomach to other areas of the body. Approximately 351 patients will be participating in this study. The study is composed of a screening period, a treatment period, and a follow-up period.

Начало: 27.08.2025 Край: 22.04.2028 Възраст: от 18 г.

Argentina, Austria, Brazil +12 BeOne Medicines NCT07043400

Набира участници Фаза 3

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

Invasive Mold Infections

The purpose of this study is to evaluate the efficacy and safety of fosmanogepix (administered IV or oral) for the treatment of adult patients with invasive mold infections. The study is looking for patients who have been diagnosed with invasive mold infections. The maximum study duration will be approximately 8 months, including a target study treatment duration of 84 days which can be extended up to 180 days and follow-up period. The patient will be assigned to one of two treatment cohorts: Cohort A (primary therapy): Patients will receive either the study drug or institutional standard of care antifungal treatment. Cohort B (salvage treatment; i.e. treatment given after patients did not respond to previous treatments or did not tolerate them): Patients will receive the study drug The primary aim is to compare the all cause mortality with a fixed threshold at Day 42.

Начало: 26.08.2025 Край: 01.02.2028 Възраст: от 18 г. Лечение

Australia, Austria, Belgium +9 Basilea Pharmaceutica NCT06925321

Набира участници Фаза 2

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

Atoptic Dermatitis

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

Начало: 26.08.2025 Край: 01.07.2026 Възраст: от 18 г. Лечение

New Zealand, United States Evommune, Inc. NCT07150845

Набира участници Фаза 1

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue +15

This phase I trial tests zanubrutinib in combination with sonrotoclax for treating underrepresented ethnic and racial minorities with B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Many racial and ethnic minorities face additional treatment challenges which may lead to poorer outcomes, however, there are fewer racial and ethnic minorities participating in clinical trials. Zanubrutinib, a type of tyrosine kinase inhibitor, blocks a protein called Bruton tyrosine kinase (BTK), which may help keep cancer cells from growing. Sonrotoclax works by blocking a protein called B-cell lymphoma-2 (Bcl-2). This protein helps certain types of blood cancer cells to survive and grow. When sonrotoclax blocks Bcl-2, it slows down or stops the growth of cancer cells and causes them to die. Zanubrutinib and sonrotoclax have been shown to be an effective treatment for B-cell cancers. Giving zanubrutinib in combination with sonrotoclax may be effective in treating ethnic and racial minorities with relapsed or refractory B-cell non-Hodgkin lymphoma.

Начало: 25.08.2025 Край: 31.01.2029 Възраст: от 18 г.

United States City of Hope Medical Center NCT06859008

1 … 64 65 66 67 68 … 240